ORIGINAL RESEARCH article

Front. Immunol.

Sec. Viral Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1600025

CYP1B1 Knockout Enhanced IFN-γ Production is Required but not Sufficient for Protection of Cigarette Smoke Exposed Mice against Lethal Influenza Virus Infection

Provisionally accepted
Wenxin  WuWenxin Wu1*Jeremy  S AlexanderJeremy S Alexander1J  Leland BoothJ Leland Booth1Magdalena  ChlebiczMagdalena Chlebicz2Craig  A MillerCraig A Miller3Chao  XuChao Xu1Susan  KovatsSusan Kovats2Jordan  P MetcalfJordan P Metcalf1
  • 1University of Oklahoma Health Sciences Center, Oklahoma City, United States
  • 2Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
  • 3Oklahoma State University, Stillwater, Oklahoma, United States

The final, formatted version of the article will be published soon.

Background: Cigarette smoke (CS) exposure increases the frequency and severity of respiratory influenza A virus (IAV) infections in humans and increases mortality in mice. There is evidence that Cytochrome P450 family 1 subfamily B member 1 (CYP1B1) enhances lung injury during hyperoxic exposure in animal models. We used an in vivo mouse model to assess the hypothesis that CYP1B1 modifies innate immune responses to CS and alters survival during IAV infection. Methods: We measured CYP1B1 induction in bronchial epithelial cells in smokers and nonsmokers obtained by bronchoscopy by whole transcriptome analysis. To determine whether CYP1B1 knockout (CYP KO) improves mortality and reduces lung injury in CS exposed mice, we compared the survival rates, host immune responses, and lung-to-body weight ratio of CYP KO mice with wildtype (WT) mice following challenge with IAV with or without CS-exposure. Results: CYP1B1 is one of the most highly upregulated genes in human lung epithelia derived from cigarette smokers. In CS-exposed mice, CYP1B1 knockout (CYP KO) significantly increased survival during IAV infection. In both nonsmoking (NS) and CS mice, CYP KO significantly enhanced IAV-induced increases in total immune cell numbers in bronchoalveolar lavage fluid (BALF) without causing additional lung injury. CYP KO caused a more rapid IFN-γ response to IAV infection in lungs from both NS and CSexposed mice. Specifically, we found that IFN-γ was significantly increased in BALF and in the lung at day 5 post-infection (p.i.) in these mice. Flow cytometry showed that innate lymphocytes produced early IFN-γ in the lungs of KO mice. We confirmed the importance of IFN-γ for CYP KO survival by adding IFN-γ antibody to IAV-infected CYP KO mice. IFN-γ antibody treatment of CS-exposed CYP KO mice completely abolished the improved survival rate seen in KO mice without IFN-γ antibody treatment. However, IFN-γ administration to CS-exposed WT mice did not increase survival rates as seen in CS-exposed CYP KO mice after IAV infection. Conclusions: Our results demonstrate CYP KO protects against CS enhanced susceptibility of smokers during influenza infection. IFN-γ is required but not sufficient for the protection of CS exposed CYP KO mice against lethal IAV infection.

Keywords: Influenza Virus, CYP1B1, Innate, Smoking, IFN-γ, Inflammation

Received: 25 Mar 2025; Accepted: 05 Jun 2025.

Copyright: © 2025 Wu, Alexander, Booth, Chlebicz, Miller, Xu, Kovats and Metcalf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Wenxin Wu, University of Oklahoma Health Sciences Center, Oklahoma City, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.